Roivant Sciences (ROIV), the biopharma company, rose more than 4%. Its oral drug brepocitinib met the primary efficacy goals in two Phase 3 trials for non infectious uveitis, an inflammatory eye disease that can cause vision loss. The results also showed benefits across secondary endpoints, with a regulatory filing planned for the first half of 2027.